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Table
Characteristic N[67 (%)
Male 49 (73)
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107S80Patients who undergo AlloHCT with isolated CNS relapse
have superior outcome compared to those with combined
CNS and BM relapse or CNS involvement at diagnosis.Female 18 (27)
Age at Transplant
</30 31 (46)
>30 36 (54)
WBC at Diagnosis (x109/L)
<100 40 (60)
>100 8 (12)
Unknown 19 (28)
Extramedullary Disease at Dx
Yes 37 (55)
No 31 (45)
CNS Disease
Yes 8 (17)
No 5 (87)
Unk 1 (6)
Cytogenetics (SWOG)
Intermediate 37 (55)
High 2 (3)
Very High 4 (6)
BCR-ABL 2 (3)
Unknown 22 (33)
Disease Status at Transplant
CR1 21 (31)
CR2+ 31 (46)
NR/PD 15 (22)
Donor Source
Unrelated 29 (43)
Sibling 35 (52)
Parent 3 (5)
Stem Cell Source
BM 18 (27)
PBSC 42 (63)
CB 7 (10)
TBI 22 (33)
No TBI 45 (67)
Figure.72
Allogeneic Stem Cell Transplantation (Allo-SCT) for the
Treatment of T-Cell Acute Lymphoblastic Leukemia
(T-ALL); Evaluation of Minimal Residual Disease and
Prognostic Factors at the MD Anderson Cancer Center
(MDACC)
Jonathan E. Brammer 1, Rima Saliba 1, Hagop Kantarjian 2,
Deborah Thomas 3, Jeffrey L. Jorgensen 4, Sameh Gaballa 1,
Celina Ledesma 5, Uday R. Popat 1, Elizabeth J. Shpall 1,
Richard E. Champlin 1, Chitra Hosing 1, Partow Kebriaei 1. 1 Stem
Cell Transplantation and Cellular Therapy, The University of
Texas MD Anderson Cancer Center, Houston, TX; 2 Department
of Leukemia, M.D. Anderson Cancer Center, Houston, TX;
3 Leukemia, MD Anderson Cancer Center, Houston, TX;
4Hematopathology, The University of Texas MD Anderson
Cancer Center, Houston, TX; 5 Department of Stem Cell
Transplantation and Cellular Therapy, University of Texas, MD
Anderson Cancer Center, Houston, TX
Introduction: T-ALL represents 20-25% of all cases of ALL,
with cure rates of 40% with chemotherapy alone. Allo-SCT
can improve survival in ﬁrst remission (CR1), and is the only
curative therapy for patients with relapsed or refractory
disease. We performed a review of all cases of T-ALL treated
with Allo-SCT at MDACC with the aim of identifying prog-
nostic markers to improve outcomes.
Methods: All patients who received ﬁrst allo-SCT for T-ALL
between 2000-2014were analyzed. Overall survival (OS) and
progression free survival (PFS) were estimated using the
Kaplan-Meier method. Cumulative incidence (CI) of relapse
(CIR), acute GVHD (aGVHD), and chronic GVHD (cGVHD)
were determined utilizing the cumulative incidence method
to account for competing risks. Given that disease relapse
was the primary cause of treatment failure, we evaluated
prognostic factors for relapse using Cox Proportional Haz-
ards regression analysis on univariate and multivariate
analysis.
Results: 67 patients received ﬁrst allo-SCT, with a median
age of 31 years (range 2-70), and a median follow-up time
among survivors of 35 months. 93% of patients received
myeloablative (MA) conditioning, with primarilytacroli-
mus/methotrexate +/- ATG GVHD prophylaxis (Table) The
3-year OS estimate was 34%, and 3-year PFS was 32%. In
patients transplanted in CR1, the OS was 57%, in CR2+,
30%, and in no-response/progressive disease (NR/PD) was
13%. The 3-year CIR was 54%, CI NRM 10% and CI cGVHD
23%. 100-day CIR II-IV aGVHD was 42%. On multivariate
analysis, male sex (HR 2.4, p¼0.055), and PD/NR (HR 2.9,
p¼0.003) were the only signiﬁcant predictors of relapse.
Minimal residual disease (MRD) by ﬂow cytometry at
transplant was predictive for relapse (HR 2.5, p¼0.03) on
univariate, but could not be analyzed on multivariate
analysis due to low numbers (n¼10), though 8/10 patients
died of relapse. CR1 vs CR2 on univariate was borderline
signiﬁcant (HR 3.96, p¼0.06). T-Cell subtyping will be
available at the time of presentation.
Conclusion:We present the largest single institutional study
of patients with T-ALL to date. Relapsewas themajor cause of
death in this cohort, with male sex and resistance to
chemotherapy as independent predictors of progression,
while transplant in CR1 trended to be advantageous for OS.
Novel strategies to decreaseMRD and relapse post transplant
are needed to improve outcomes.73
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Background: Allogeneic HCT is used commonly in adults
with ALL. MRD is an accepted prognostic factor in ALL. Being
MRD-negative (MRDNeg) overcomes age and cytogenetics
(CG; Bassan, Blood, 2009), and it is predictive of outcome
without (No) HCT and prior to myeloablative (MAC) and
reduced-intensity HCT (RIC). However, comparisons of these
treatments in this favorable-risk subgroup are limited. We
sought to examine outcomes with these 3 approaches
exclusively in pts in ﬁrst MRDNeg remission (MRDNeg CR1).
Methods: We performed a retrospective analysis of pts that
were diagnosed or referred for HCT at our Center since 2005.
MRDNeg was deﬁned as undetectable by all methods used:
Multiparameter ﬂow cytometry was used in all pts, though
other measures (PCR, FISH, and/or CG) were considered if
performed. Clinical risk factors at diagnosis (dx) included age
 35, high white blood count (WBC; > 30 in B-ALL, > 100 in
T-ALL), and adverse CG (Ph+, low hypodiploid/near triploid,
complex [ 5 abnormalities], MLL rearranged, t[8;14], -7, and
+8). Group characteristics were compared with Fisher’s exact
test. Kaplan-Meier plots and Cox proportional hazardmodels
were used to investigate associations between variables.
Results: Of 127 pts identiﬁed, 53 (42%) received MAC, 19
(15%) received RIC, and 55 (43%) No HCT while in MRDNeg
CR1. RIC pts were signiﬁcantly more likely than MAC and No
HCT pts to be  35 years old at dx (89% vs 60% vs 51%,
respectively [resp.]; P¼ 0.0084) and have adverse CG (83% vs
53% vs 30%, resp.; P < 0.001). There were no signiﬁcant dif-
ferences inWBC at dx, initial therapy received, or (among the
HCT groups) stem-cell donor or product. All Ph+ pts received
tyrosine kinase inhibitors.
Overall survival (OS) from dx in these 3 groups was
similar (P¼ 0.35; Fig 1), though relapse was signiﬁcantly less
with MAC (P ¼ 0.01; Fig 2). 3-year (yr) estimates of OS with
MAC, RIC, and No HCT were 71%, 73%, and 75% (resp.), and
30%, 51%, and 60% (resp.) for relapse. 3-yr non-relapse mor-
tality was 17% with MAC vs 5% with RIC (P¼ 0.15). Compared
to No HCT, the risk of death was not different with MACFig 1. OS from diagnosis among pts in MRDNeg CR1.(hazard ratio [HR] 1.6, P ¼ 0.19) or RIC (HR 1.0, P ¼ 1.0),
adjusted for WBC. However, relapse was lower with HCT,
adjusted for WBC and (due to more events) adverse CG:
signiﬁcantly so after MAC (HR 0.35, P ¼ 0.0014) but not with
RIC (HR 0.57, P ¼ 0.18). OS was also similar with Ph+ and Ph-
studied separately (P ¼ 0.99 and 0.14, resp.).
In a distinct analysis of 23 pts who underwent HCT while
MRDNeg beyond CR1 (CR2+), OS from HCT was comparable
for CR1 and CR2+ (P ¼ 0.46). 3-yr estimates of OS were 69%
and 62% (resp.).
Conclusions: Among contemporary adults with ALL in
MRDNeg CR1, RIC pts were more commonly older with
adverse CG. MAC yielded signiﬁcantly less relapse, but OS
was no different thanwith RIC or No HCT. HCT while MRDNeg
yields similar outcomes in CR1 and CR2+. For pts in MRDNeg
CR1, the role of up-front HCT is less clear.
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Introduction: FLT3mutations are present inup to30%ofAML
pts with diploid cytogenetics. Allogeneic hematopoietic stem
cell transplantation (AlloSCT) has emerged as the preferred
therapy for this high-risk group, but these pts remain at high
risk for disease relapse. The signiﬁcance of FLT3 detection by
PCR, as a minimal residual disease marker, at the time of
AlloSCT remains unclear and little is known about the risk
factors associated with risk of relapse among FLT3 AML pts.
Methods: We reviewed 1255 AML pts who underwent ﬁrst
AlloSCT between 2000 and 2014, and identiﬁed 200 adult pts
with a FLT3-ITD or FLT3-TKD mutation found at diagnosis
